BRPI0918555A2 - anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição. - Google Patents

anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.

Info

Publication number
BRPI0918555A2
BRPI0918555A2 BRPI0918555A BRPI0918555A BRPI0918555A2 BR PI0918555 A2 BRPI0918555 A2 BR PI0918555A2 BR PI0918555 A BRPI0918555 A BR PI0918555A BR PI0918555 A BRPI0918555 A BR PI0918555A BR PI0918555 A2 BRPI0918555 A2 BR PI0918555A2
Authority
BR
Brazil
Prior art keywords
composition
antibody
animal
treating
nucleic acid
Prior art date
Application number
BRPI0918555A
Other languages
English (en)
Portuguese (pt)
Inventor
Gadi Gazit-Bornstein
John Babcook
Naomi Laing
Qing Zhou
Simon Thomas Barry
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BRPI0918555A2 publication Critical patent/BRPI0918555A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0918555A 2008-09-19 2009-09-18 anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição. BRPI0918555A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9868508P 2008-09-19 2008-09-19
PCT/GB2009/051216 WO2010032059A2 (en) 2008-09-19 2009-09-18 Targeted binding agents directed to cd105 and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0918555A2 true BRPI0918555A2 (pt) 2016-05-03

Family

ID=41263674

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918555A BRPI0918555A2 (pt) 2008-09-19 2009-09-18 anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.

Country Status (9)

Country Link
US (1) US20100196398A1 (enExample)
EP (1) EP2344541A2 (enExample)
JP (1) JP2012502649A (enExample)
KR (1) KR20110057245A (enExample)
CN (1) CN102388067A (enExample)
AU (1) AU2009294414A1 (enExample)
BR (1) BRPI0918555A2 (enExample)
CA (1) CA2737667A1 (enExample)
WO (1) WO2010032059A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN00313A (enExample) * 2003-06-27 2015-05-08 Amgen Fremont Inc
EP2064325B1 (en) 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
DK2370466T3 (en) 2008-12-19 2015-08-03 Univ Zuerich Humane anti-alpha-synuclein-autoantistoffer
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
TWI636993B (zh) 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
CA2827952A1 (en) 2011-02-23 2012-11-01 Health Research, Inc. Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
CA2828000A1 (en) * 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
CA2839563C (en) * 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
WO2013074840A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Treatment of dry age related macular degeneration
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
CN108347906A (zh) * 2015-10-29 2018-07-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
CN106928355B (zh) * 2015-12-30 2020-09-29 广西医科大学 一种CD105纳米抗体Nb184
CN106928359B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种CD105纳米抗体Nb59
RU2732502C2 (ru) 2016-02-10 2020-09-18 Ратгерс, Де Стейт Юниверсити Оф Нью Джерси Новые моноклональные антитела к LAM и PIM6/LAM для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis
CA3026066A1 (en) * 2016-06-14 2017-12-21 Cedars-Sinai Medical Center Sensitization of tumors to therapies through endoglin antagonism
DK3672631T5 (da) 2017-08-22 2024-08-26 Biogen Ma Inc Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
CN108912212B (zh) * 2018-06-28 2019-08-30 中山大学附属口腔医院 一种与cd105特异性结合的多肽及其应用
WO2020106461A2 (en) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2021207433A2 (en) * 2020-04-07 2021-10-14 The Regents Of The University Of California Epitopes of sars-cov-2 neutralizing antibodies
CN112426526B (zh) * 2021-01-25 2021-04-06 北京达熙生物科技有限公司 一种nk细胞的制备方法及其在治疗癌症中的应用
CN112876538B (zh) * 2021-02-04 2022-09-30 福建医科大学 靶向新生血管标记物cd105的多肽及其应用
EP4301785A4 (en) 2021-03-05 2025-04-23 Atreca, Inc. EPHA2 ANTIBODIES
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
IL314048A (en) * 2022-01-24 2024-09-01 Genovac Antibody Discovery Llc Anti-alk1 antibodies and methods of using the same
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4627096A1 (en) 2022-12-02 2025-10-08 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
CN121443743A (zh) 2023-05-23 2026-01-30 赛纳生物技术公司 串联融合剂和相关脂质颗粒
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025045032A1 (zh) * 2023-08-29 2025-03-06 应世生物科技(南京)有限公司 一种靶向cd105的抗体或其抗原结合片段及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
KR20250174161A (ko) * 2024-06-04 2025-12-12 한국과학기술연구원 엔도글린 및 메소테린 이중 항원 표적 car 및 이의 용도
TWI882851B (zh) * 2024-06-27 2025-05-01 蔡政育 基於專利技術元素整合之專利分析系統及其方法
WO2026017807A1 (en) 2024-07-18 2026-01-22 Beech Biotech Sa Compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190660B1 (en) * 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
PT2275449T (pt) * 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys

Also Published As

Publication number Publication date
WO2010032059A2 (en) 2010-03-25
CN102388067A (zh) 2012-03-21
US20100196398A1 (en) 2010-08-05
CA2737667A1 (en) 2010-03-25
WO2010032059A3 (en) 2010-06-24
KR20110057245A (ko) 2011-05-31
EP2344541A2 (en) 2011-07-20
JP2012502649A (ja) 2012-02-02
AU2009294414A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
BRPI0918555A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.
BRPI0918739A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de tumor maligno em animais, e, uso da composição.
LTC2100614I2 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0919377A2 (pt) anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BRPI0922106A2 (pt) anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
BR112012003809A2 (pt) anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
BRPI0813311A2 (pt) Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
BRPI0916121A2 (pt) "métodos para identificar câncer de próstata, método para identificar a presença de uma fusão gênica, kit e uso de uma composição"
BRPI0714876A2 (pt) glucanases, ácidos nucleicos codificando as mesmas e métodos para fabricar e usar as mesmas.
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BRPI0918122A8 (pt) molécula de diabody, diabody, e mólecula dart
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
BRPI0722053A2 (pt) método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina
BRPI0919488A2 (pt) composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BR112013007229A2 (pt) ''composição,mistura e processo''.
BRPI0811755A2 (pt) Amplificação específica de senquência de dna específicas de tumor.
BRPI0822218A2 (pt) Transferases e oxidorredutases, ácidos nucleicos que as codificam e métodos para fazê-las e usá-las.
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0911252A2 (pt) método, extrato, e, composição.
BRPI0822472A2 (pt) Método, camundongo, e, composição
EP2281903A4 (en) CANCER MARKER, METHOD FOR EVALUATING CANCER USING THE CANCER MARKER AND ASSESSING THE VALUE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.